Transforming growth factor Beta2 is required for valve remodeling during heart development

Developmental Dynamics

Volumn 240, Issue 9, 2011, Pages 2127-2141

  Azhar, Mohamad ^a,b   Brown, Kristen ^a   Gard, Connie ^a   Chen, Hwudaurw ^b   Rajan, Sudarsan ^c   Elliott, David A ^b   Stevens, Mark V ^a   Camenisch, Todd D ^a,b   Conway, Simon J ^d   Doetschman, Thomas ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart development; Transforming growth factor beta; Valves

Indexed keywords

CARTILAGE LINK PROTEIN 1; HYALURONIC ACID; SCLEROPROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; EMBRYO; EXTRACELLULAR MATRIX; HEART DEVELOPMENT; HEART VALVE; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; HEART; HEART VALVES; IMMUNOHISTOCHEMISTRY; MESODERM; MICE; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

EID: 80051685812     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.22702     Document Type: Article

References (80)

1. Abdelwahid E, Pelliniemi LJ, Jokinen E. 2002. Cell death and differentiation in the development of the endocardial cushion of the embryonic heart. Microsc Res Tech 58: 395-403.
2. Amara FM, Entwistle J, Kuschak TI, Turley EA, Wright JA. 1996. Transforming growth factor-beta1 stimulates multiple protein interactions at a unique cis-element in the 3'-untranslated region of the hyaluronan receptor RHAMM mRNA. J Biol Chem 271: 15279-15284.
3. Arthur HM, Bamforth SD. 2011. TGFbeta signaling and congenital heart disease: insights from mouse studies. Birth Defects Res A Clin Mol Teratol 91: 423-434.
4. Avagyan S, Glouchkova L, Choi J, Snoeck HW. 2008. A quantitative trait locus on chromosome 4 affects cycling of hematopoietic stem and progenitor cells through regulation of TGF-beta 2 responsiveness. J Immunol 181: 5904-5911.
5. Azhar M, Schultz JE, Grupp I, Dorn GW, Meneton P, Molin DG, Gittenberger-de Groot AC, Doetschman T. 2003. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 14: 391-407.
6. Azhar M, Runyan RB, Gard C, Sanford LP, Miller ML, Andringa A, Pawlowski S, Rajan S, Doetschman T. 2009. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev Dyn 238: 431-442.
7. Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, Speer CP, Poelmann RE, Gittenberger-de Groot AC. 2001. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in Tgfb2 knockout mice. Circulation 103: 2745-2752.
8. Bouman HG, Broekhuizen LA, Baasten AM, Gittenberger-de Groot AC, Wenink AC. 1997. Stereological study of stage 34 chicken hearts with looping disturbances after retinoic acid treatment: disturbed growth of myocardium and atrioventricular cushion tissue. Anat Rec 248: 242-250.
9. Brewer RJ, Mentzer RM Jr, Deck JD, Ritter RC, Trefil JS, Nolan SP. 1977. An in vivo study of the dimensional changes of the aortic valve leaflets during the cardiac cycle. J Thorac Cardiovasc Surg 74: 645-650.
10. Brown CB, Boyer AS, Runyan RB, Barnett JV. 1999. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 283: 2080-2082.
11. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. 2006. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47: 1707-1712.
12. Chakraborty S, Cheek J, Sakthivel B, Aronow BJ, Yutzey KE. 2008. Shared gene expression profiles in developing heart valves and osteoblast progenitor cells. Physiol Genomics 35: 75-85.
13. Charitakis K, Basson CT. 2007. Degenerating heart valves: fill them up with filamin? Circulation 115: 2-4.
14. Daly AC, Randall RA, Hill CS. 2008. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28: 6889-6902.
15. Delaughter DM, Saint-Jean L, Baldwin HS, Barnett JV. 2011. What chick and mouse models have taught us about the role of the endocardium in congenital heart disease. Birth Defects Res A Clin Mol Teratol 91: 511-525.
16. Derynck R, Akhurst RJ. 2007. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 9: 1000-1004.
17. Egorova AD, Khedoe PP, Goumans MJ, Yoder BK, Nauli SM, ten Dijke P, Poelmann RE, Hierck BP. 2011. Lack of primary cilia primes shear-induced endothelial-to-mesenchymal transition. Circ Res 108: 1093-1101.
18. Elliott DA, McIntosh MT, Hosgood HD III, Chen S, Zhang G, Baevova P, Joiner KA. 2008. Four distinct pathways of hemoglobin uptake in the malaria parasite Plasmodium falciparum. Proc Natl Acad Sci U S A 105: 2463-2468.
19. Evanko SP, Raines EW, Ross R, Gold LI, Wight TN. 1998. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol 152: 533-546.
20. Fackler MJ, Krause DS, Smith OM, Civin CI, May WS. 1995. Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells. Blood 85: 3040-3047.
21. Garcia-Martinez V, Sanchez-Quintana D, Hurle JM. 1991. Histochemical and ultrastructural changes in the extracellular matrix of the developing chick semilunar heart valves. Acta Anat (Basel) 142: 87-96.
22. Gitler AD, Zhu Y, Ismat FA, Lu MM, Yamauchi Y, Parada LF, Epstein JA. 2003. Nf1 has an essential role in endothelial cells. Nat Genet 33: 75-79.
23. Gittenberger-de Groot AC, Azhar M, Molin DG. 2006. Transforming growth factor beta-SMAD2 signaling and aortic arch development. Trends Cardiovasc Med 16: 1-6.
24. Grande-Allen KJ, Osman N, Ballinger ML, Dadlani H, Marasco S, Little PJ. 2007. Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease. Cardiovasc Res 76: 19-28.
25. Gundersen HJ, Jensen EB. 1987. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229-263.
26. Hinton RB, Yutzey KE. 2011. Heart valve structure and function in development and disease. Annu Rev Physiol 73: 29-46.
27. Hinton RB Jr, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE. 2006. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 98: 1431-1438.
28. Hinton RB, Adelman-Brown J, Witt S, Krishnamurthy VK, Osinska H, Sakthivel B, James JF, Li DY, Narmoneva DA, Mecham RP, Benson DW. 2010. Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circ Res 107: 549-557.
29. Hoover LL, Burton EG, O'Neill ML, Brooks BA, Sreedharan S, Dawson NA, Kubalak SW. 2008. Retinoids regulate TGFbeta signaling at the level of Smad2 phosphorylation and nuclear accumulation. Biochim Biophys Acta 1783: 2279-2286.
30. Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. 2003. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75: 457-465.
31. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11: 415-421.
32. Kang JS, Liu C, Derynck R. 2009. New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 19: 385-394.
33. Kern CB, Twal WO, Mjaatvedt CH, Fairey SE, Toole BP, Iruela-Arispe ML, Argraves WS. 2006. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev Dyn 235: 2238-2247.
34. Kofler J, Hattori K, Sawada M, DeVries AC, Martin LJ, Hurn PD, Traystman RJ. 2004. Histopathological and behavioral characterization of a novel model of cardiac arrest and cardiopulmonary resuscitation in mice. J Neurosci Methods 136: 33-44.
35. Krause DS, Fackler MJ, Civin CI, May WS. 1996. CD34: structure, biology, and clinical utility. Blood 87: 1-13.
36. Kruithof BP, Krawitz SA, Gaussin V. 2007. Atrioventricular valve development during late embryonic and postnatal stages involves condensation and extracellular matrix remodeling. Dev Biol 302: 208-217.
37. Lakkis MM, Epstein JA. 1998. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125: 4359-4367.
38. Levay AK, Peacock JD, Lu Y, Koch M, Hinton RB Jr, Kadler KE, Lincoln J. 2008. Scleraxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. Circ Res 103: 948-956.
39. Li P, Pashmforoush M, Sucov HM. 2010. Retinoic acid regulates differentiation of the secondary heart field and TGFbeta-mediated outflow tract septation. Dev Cell 18: 480-485.
40. Lincoln J, Yutzey KE. 2011. Molecular and developmental mechanisms of congenital heart valve disease. Birth Defects Res A Clin Mol Teratol 91: 526-534.
41. Lincoln J, Lange AW, Yutzey KE. 2006a. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol 294: 292-302.
42. Lincoln J, Florer JB, Deutsch GH, Wenstrup RJ, Yutzey KE. 2006b. ColVa1 and ColXIa1 are required for myocardial morphogenesis and heart valve development. Dev Dyn 235: 3295-3305.
43. Maki JM, Rasanen J, Tikkanen H, Sormunen R, Makikallio K, Kivirikko KI, Soininen R. 2002. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 106: 2503-2509.
44. Markwald RR, Norris RA, Moreno-Rodriguez R, Levine RA. 2010. Developmental basis of adult cardiovascular diseases: valvular heart diseases. Ann N Y Acad Sci 1188: 177-183.
45. Matsumoto K, Shionyu M, Go M, Shimizu K, Shinomura T, Kimata K, Watanabe H. 2003. Distinct interaction of versican/PG-M with hyaluronan and link protein. J Biol Chem 278: 41205-41212.
46. Mercado-Pimentel ME, Runyan RB. 2007. Multiple transforming growth factor-beta isoforms and receptors function during epithelial-mesenchymal cell transformation in the embryonic heart. Cells Tissues Organs 185: 146-156.
47. Mizushige K, Masugata H, Senda S, Manabe K, Sakamoto H, Kinoshita A, Sakamoto S, Matsuo H. 1999. Cyclic variation of thickness in an age-related thick mitral valve observed by transthoracic echocardiography. Angiology 50: 735-743.
48. Molin DG, Bartram U, Van der Heiden K, Van Iperen L, Speer CP, Hierck BP, Poelmann RE, Gittenberger-de Groot AC. 2003. Expression patterns of Tgfbeta1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton. Dev Dyn 227: 431-444.
49. Moon A. 2008. Mouse models of congenital cardiovascular disease. Curr Top Dev Biol 84: 171-248.
50. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. 2004. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114: 1586-1592.
51. Peacock JD, Lu Y, Koch M, Kadler KE, Lincoln J. 2008. Temporal and spatial expression of collagens during murine atrioventricular heart valve development and maintenance. Dev Dyn 237: 3051-3058.
52. Peacock JD, Levay AK, Gillaspie DB, Tao G, Lincoln J. 2010. Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res 106: 712-719.
53. Person AD, Klewer SE, Runyan RB. 2005. Cell biology of cardiac cushion development. Int Rev Cytol 243: 287-335.
54. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
55. Pierelli L, Marone M, Bonanno G, Rutella S, de Ritis D, Mancuso S, Leone G, Scambia G. 2002. Transforming growth factor-beta1 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity. Br J Haematol 118: 627-637.
56. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T. 1995. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11: 409-414.
57. Ramirez F, Rifkin DB. 2009. Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. Curr Opin Cell Biol 21: 616-622.
58. Ross S, Hill CS. 2008. How the Smads regulate transcription. Int J Biochem Cell Biol 40: 383-408.
59. Sanford LP, Ormsby I, Gittenberger-de GA, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. 1997. TGFbeta2 knockout mice have multiple developmental defects that are non- overlapping with other TGFbeta knockout phenotypes. Development 124: 2659-2670.
60. Schroeder JA, Jackson LF, Lee DC, Camenisch TD. 2003. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J Mol Med 81: 392-403.
61. Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, Frazer JR, Sun S, Baker AL, Newburger JW, Rowley AH, Shulman ST, Davila S, Burgner D, Breunis WB, Kuijpers TW, Wright VJ, Levin M, Eleftherohorinou H, Coin L, Popper SJ, Relman DA, Fury W, Lin C, Mellis S, Tremoulet AH, Burns JC. 2011. Transforming growth factor-{beta} signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 4: 16-25.
62. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Doetschman T. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
63. Snider P, Conway SJ. 2011. Probing human cardiovascular congenital disease using transgenic mouse models. Prog Mol Biol Transl Sci 100: 83-110.
64. Snider P, Hinton RB, Moreno-Rodriguez RA, Wang J, Rogers R, Lindsley A, Li F, Ingram DA, Menick D, Field L, Firulli AB, Molkentin JD, Markwald R, Conway SJ. 2008. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res 102: 752-760.
65. Sporn MB, Roberts AB. 1990. TGF-beta: problems and prospects. Cell Regul 1: 875-882.
66. Supino PG, Borer JS, Preibisz J, Bornstein A. 2006. The epidemiology of valvular heart disease: a growing public health problem. Heart Fail Clin 2: 379-393.
67. Tang S, Snider P, Firulli AB, Conway SJ. 2010. Trigenic neural crest-restricted Smad7 over-expression results in congenital craniofacial and cardiovascular defects. Dev Biol 344: 233-247.
68. ten Dijke P, Arthur HM. 2007. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869.
69. Todorovic V, Finnegan E, Freyer L, Zilberberg L, Ota M, Rifkin DB. 2011. Long form of latent TGF-beta binding protein 1 (Ltbp1L) regulates cardiac valve development. Dev Dyn 240: 176-187.
70. Townsend TA, Robinson JY, Deig CR, Hill CR, Misfeldt A, Blobe GC, Barnett JV. 2011. BMP-2 and TGFbeta2 shared pathways regulate endocardial cell transformation. Cells Tissues Organs 194: 1-12.
71. Traore Y, Hirn J. 1994. Certain anti-CD34 monoclonal antibodies induce homotypic adhesion of leukemic cell lines in a CD18-dependent and a CD18-independent way. Eur J Immunol 24: 2304-2311.
72. van de Laar I, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen LA, Venselaar H, Vriend G, Pattynama PM, Collee M, Majoor-Krakauer D, Poldermans D, Frohn-Mulder IM, Micha D, Timmermans J, Hilhorst-Hofstee Y, Bierma-Zeinstra SM, Willems PJ, Kros JM, Oei EH, Oostra BA, Wessels MW, Bertoli-Avella AM. 2011. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 43: 121-126.
73. Visconti RP, Ebihara Y, LaRue AC, Fleming PA, McQuinn TC, Masuya M, Minamiguchi H, Markwald RR, Ogawa M, Drake CJ. 2006. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res 98: 690-696.
74. Vrljicak PJ, Chang AC, Morozova O, Wederell ED, Niessen K, Marra MA, Karsan A, Hoodless PA. 2009. Genomic analysis distinguishes phases of early development of the mouse atrio-ventricular canal. Physiol Genomics 40: 150-157.
75. Wang J, Sridurongrit S, Dudas M, Thomas P, Nagy A, Schneider MD, Epstein JA, Kaartinen V. 2005. Atrioventricular cushion transformation is mediated by ALK2 in the developing mouse heart. Dev Biol 286: 299-310.
76. Wirrig EE, Yutzey KE. 2011. Transcriptional regulation of heart valve development and disease. Cardiovasc Pathol 20: 162-167.
77. Wirrig EE, Snarr BS, Chintalapudi MR, O'Neal JL, Phelps AL, Barth JL, Fresco VM, Kern CB, Mjaatvedt CH, Toole BP, Hoffman S, Trusk TC, Argraves WS, Wessels A. 2007. Cartilage link protein 1 (Crtl1), an extracellular matrix component playing an important role in heart development. Dev Biol 310: 291-303.
78. Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, Epstein JA. 2009. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105: 304-311.
79. Xu S, Grande-Allen KJ. 2010. The role of cell biology and leaflet remodeling in the progression of heart valve disease. Methodist Debakey Cardiovasc J 6: 2-7.
80. Zanetti M, Braghetta P, Sabatelli P, Mura I, Doliana R, Colombatti A, Volpin D, Bonaldo P, Bressan GM. 2004. EMILIN-1 deficiency induces elastogenesis and vascular cell defects. Mol Cell Biol 24: 638-650.